Compare Moderna, Inc. (MRNA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ProShares UltraPro S&P500 — how do they compare? Moderna, Inc. trades at $207.2 (market cap $78.65B), while ProShares UltraPro S&P500 trades at $154.76 (market cap $5.55B). The key difference: Moderna, Inc. is far larger — about 14.2× ProShares UltraPro S&P500's market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 2,078,694). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and ProShares UltraPro S&P500 for 29 Days on average.
| MRNA | UPRO | |
|---|---|---|
Market Cap | $78.65B | $5.55B |
Volume | 37,373,437 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $203.46 | $157.66 |
52-Week Low | $22.36 | $89.29 |
Typical Hold Time | 59 Days | 29 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
UPRO trades at $155.21, down 0.77% for the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces resistance near $156-$160 with support at $151-$147. Recent news highlights S&P 500 valuation concerns and projected earnings growth slowdown from 35% in 2026 to 15% in 2027, creating mixed sentiment around leveraged ETF performance.
Outlook remains cautiously optimistic given the bullish technical setup, though leveraged nature amplifies risks from market volatility and earnings growth deceleration. Key opportunities include potential year-end rally patterns, while risks center on concentrated market exposure and macroeconomic headwinds affecting the underlying index performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
